Introduction of Tapasin Gene Restores Surface Expression of HLA Class I Molecules, but Not Antigen Presentation of an HIV Envelope Peptide in a Hepatoma Cell Line

2001 ◽  
Vol 285 (2) ◽  
pp. 508-517 ◽  
Author(s):  
Masanori Matsui ◽  
Sanae Machida ◽  
Hiroko Tomiyama ◽  
Masafumi Takiguchi ◽  
Toshitaka Akatsuka
Keyword(s):  
Antigen Presentation ◽  
Cell Line ◽  
Hepatoma Cell ◽  
Hla Class I ◽  
Surface Expression ◽  
Class I ◽  
Hepatoma Cell Line ◽  
Hla Class I Molecules ◽  
Hiv Envelope

Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells

Blood ◽  
2002 ◽  
Vol 99 (5) ◽  
pp. 1723-1729 ◽  
Author(s):  
Massimo Vitale ◽  
Jacques Zimmer ◽  
Roberta Castriconi ◽  
Daniel Hanau ◽  
Lionel Donato ◽  
...  
Keyword(s):  
Nk Cells ◽  
Natural Killer ◽  
Antigen Processing ◽  
Nk Cell ◽  
Hla Class I ◽  
Surface Expression ◽  
Class I ◽  
Inhibitory Receptor ◽  
Surface Receptors ◽  
Hla Class I Molecules

Natural killer (NK) cells are characterized by the ability to kill cells that lack HLA class I molecules while sparing autologous normal (HLA class I+) cells. However, patients with transporter-associated antigen processing (TAP) deficiency, though displaying strong reductions of HLA class I surface expression, in most instances do not experience NK-mediated autoimmune phenomena. A possible mechanism by which TAP−/− NK cells avoid autoreactivity against autologous HLA class I–deficient cells could be based on either quantitative or qualitative defects of surface receptors involved in NK cell triggering. In this study we show that NK cells derived from 2 patients with TAP2−/− express normal levels of all known triggering receptors. As revealed by the analysis of polyclonal and clonal NK cells, these receptors display normal functional capabilities and allow the killing of a panel of NK-susceptible targets, including autologous B-LCLs. On the other hand, TAP2−/− NK cells were unable to kill either allogeneic (HLA class I+) or autologous (HLA class I− ) phytohemagglutinin (PHA) blasts even in the presence of anti-HLA class I monoclonal antibody. These data suggest that TAP2−/− NK cells express still unknown inhibitory receptor(s) capable of down-regulating the NK cell cytotoxicity on binding to surface ligand(s) expressed by T cell blasts. Functional analyses, both at the polyclonal and at the clonal level, are consistent with the concept that the putative inhibitory receptor is expressed by virtually all TAP2−/− NK cells, whereas it is present only in rare NK cells from healthy persons. Another possibility would be that TAP2−/− NK cells are missing a still unidentified triggering receptor involved in NK cell-mediated killing of PHA blasts.

Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules

The Lancet ◽  
1999 ◽  
Vol 354 (9190) ◽  
pp. 1598-1603 ◽  
Author(s):  
Hélène T Moins-Teisserenc ◽  
Stephan D Gadola ◽  
Marina Cella ◽  
P Rod Dunbar ◽  
Andrew Exley ◽  
...  
Keyword(s):  
Wegener’S Granulomatosis ◽  
Hla Class I ◽  
Surface Expression ◽  
Wegener's Granulomatosis ◽  
Class I ◽  
Hla Class I Molecules

scholarly journals Expression and function of CD8 in a murine T cell hybridoma.

1987 ◽  
Vol 166 (6) ◽  
pp. 1747-1757 ◽  
Author(s):  
S E Ratnofsky ◽  
A Peterson ◽  
J L Greenstein ◽  
S J Burakoff
Keyword(s):  
T Cell ◽  
Cell Line ◽  
T Cell Activation ◽  
Cell Activation ◽  
Hla Class I ◽  
Class Ii ◽  
Class I ◽  
Parent Cell ◽  
Class I Mhc ◽  
Hla Class I Molecules

In general, the human CD8 molecule is expressed on T cells specific for HLA class I molecules. Studies designed to delineate the function and to define the ligand of the CD8 molecule have been complicated by the fact that the presumptive ligand for CD8 is on the HLA class I molecule, the same molecule encoding the ligand for the antigen-specific T cell receptor. The ability to express genes in cells other than their natural host has produced a new technology with which to approach CD8 functional studies. The insertion of a cDNA clone for CD8 in a defective retroviral vector has allowed the transfer of CD8 by infection with the resulting defective retrovirus. CD8 was then expressed in an HLA class II-specific T cell, thus separating the ligand requirements of the TCR and CD8. By this approach, the human CD8 molecule was expressed in a murine T cell hybridoma specific for human class II antigens. The resulting CD8+ hybridomas demonstrated a 10-fold increase in IL-2 production over the parent cell line when stimulated with JY, a human B lymphoblastoid cell line expressing both class I and II HLA antigens, demonstrating that expression of CD8 increases T cell activation. mAbs directed against the CD8 molecule inhibited the response of CD8+ hybridomas to JY, supporting the conclusion that the CD8 molecule was fractional. The role of CD8 as a receptor for class I MHC antigens was addressed by stimulation with a cell line expressing HLA-DR antigens, but lacking the expression of HLA class I antigens (Daudi). Stimulation of the CD8+ hybridomas by Daudi did not result in increased IL-2 production. The response to Daudi was unaltered by the addition of anti-CD8 mAb, in contrast to the ability of anti-CD8 mAb to block JY stimulation. Furthermore, mAbs directed against the class I antigens present on JY cells were able to block the enhanced response of the CD8+ hybridomas to JY. These data support the hypothesis that HLA class I molecules are the ligands involved in the CD8-dependent enhancement of T cell activation.

844 Immunomodulatory activity of epigenetic drugs combinations in mesothelioma: laying the ground for new immunotherapeutic strategies

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A896-A896
Author(s):  
Sara Cannito ◽  
Health Biology ◽  
Ornella Cutaia ◽  
Carolina Fazio ◽  
Maria Fortunata Lofiego ◽  
...  
Keyword(s):  
Cell Line ◽  
Cell Lines ◽  
Hla Class I ◽  
Class I ◽  
Immunomodulatory Activity ◽  
Epigenetic Drugs ◽  
Hla Class I Antigens ◽  
Hla Class I Molecules ◽  
Mesothelioma Cell Line ◽  
Mesothelioma Cell

BackgroundGrowing evidence are demonstrating the therapeutic efficacy of immune checkpoint inhibitors (ICI) in mesothelioma; however, a limited percentage of patients benefits from this therapeutic approach. Epigenetic modifications play a relevant role in negatively regulating the cross-talk between neoplastic and immune cells, and in contributing to the highly immunosuppressive mesothelioma microenvironment. A better understanding of mesothelioma epigenetic landscape could open the path to novel and potentially more effective approaches combining ICI and epigenetic drugs. We investigated the immunomodulatory potential of epigenetic agents by comparing the activity of DNA hypomethylating agents (DHA) with histone deacetylases inhibitors (HDACi) and EZH2 inhibitors (EZH2i), alone or combined with DHA, in mesothelioma cells.MethodsFour mesothelioma cell lines were treated with the DHA guadecitabine 1μM, or with the HDACi, Valproic Acid (VPA) 1mM, or the EZH2i, EPZ-6438 1μM, alone or combined with guadecitabine. We investigated the expression of HLA class I molecules by flow-cytometry and of PD-L1, cancer testis antigens (CTA: NY-ESO, MAGE-A1), Natural Killer Group 2 member D Ligands (NKG2DLs: MIC-A, MIC-B, ULBP2) and EMT-regulating cadherins (CDH1, CDH2) by quantitative Real-Time PCR. Fold change (FC) expression for each treatment vs untreated cells was reported as mean values (FCm) among investigated cell lines. A positive modulation of the expression was considered if FCm>1.5.ResultsGuadecitabine upregulated the expression of HLA class I antigens (FCm=1.75), PD-L1 (FCm=2.38), NKG2DLs (MIC-A FCm=1.96, MIC-B FCm=2.57, and ULBP2 FCm=3.56), and upregulated/induced CTA expression. Similarly, VPA upregulated HLA class I antigens (FCm=1.67), PD-L1 (FCm=3.17), NKG2DLs (MIC-A FCm=1.78, MIC-B FCm=3.04, and ULBP2 FCm=3.75) expression; however, CTA expression was modulated only in 1 mesothelioma cell line. Conversely, EPZ-6438 up-regulated only NY-ESO-1 and MIC-B expression in 1 mesothelioma cell line.The addition of both VPA and EPZ-6483 to guadecitabine strengthened its immunomodulatory activity. Specifically, guadecitabine plus VPA or EPZ-6438 upregulated the expression of HLA class I antigens FCm=2.55 or 2.69, PD-L1 FCm=8.04 or 2.65, MIC-A FCm=3.81 or 2.26, MIC-B FCm=8.00 or 3.03, ULBP2 FCm=6.24 or 4.53, respectively. Higher levels of CTA upregulation/induction were observed with combination treatments vs guadecitabine alone.Cadherins modulation was mesothelioma histotype-related: CDH1 expression was induced in the 2 constitutively-negative sarcomatoid mesothelioma cells by guadecitabine alone or combined with VPA or EPZ-6438; CDH2 expression was upregulated by VPA alone (FCm=1.53) or plus guadecitabine (FCm=2.54).ConclusionsCombination of DHA-based immunotherapies with other classes of epigenetic drugs could be an effective strategy to be pursued in the mesothelioma clinic.

Identification and Quantification of Antigens Associated with HLA Class I Molecules on a Bladder Tumour Cell Line

2003 ◽  
Vol 70 (3) ◽  
pp. 154-160 ◽  
Author(s):  
Nasir Torabi-Pour ◽  
W. John W. Morrow ◽  
Roghieh Saffie ◽  
Prashant G. Gowda ◽  
D. Perrett ◽  
...  
Keyword(s):  
Cell Line ◽  
Tumour Cell ◽  
Bladder Tumour ◽  
Hla Class I ◽  
Class I ◽  
Tumour Cell Line ◽  
Hla Class I Molecules ◽  
Identification And Quantification

scholarly journals A Micropolymorphism Altering the Residue Triad 97/114/156 Determines the Relative Levels of Tapasin Independence and Distinct Peptide Profiles for HLA-A*24 Allotypes

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Soumya Badrinath ◽  
Heike Kunze-Schumacher ◽  
Rainer Blasczyk ◽  
Trevor Huyton ◽  
Christina Bade-Doeding
Keyword(s):  
Significant Risk ◽  
Hla Class I ◽  
Surface Expression ◽  
Class I ◽  
Cell Surface Expression ◽  
Hematopoietic Stem ◽  
Hla Class I Molecules ◽  
Peptide Loading ◽  
Peptide Profiles ◽  
Distinct Peptide

While many HLA class I molecules interact directly with the peptide loading complex (PLC) for conventional loading of peptides certain class I molecules are able to present peptides in a way that circumvents the PLC components. We investigated micropolymorphisms at position 156 of HLA-A*24 allotypes and their effects on PLC dependence for assembly and peptide binding specificities. HLA-A*24:06156Trpand HLA-A*24:13156Leushowed high levels of cell surface expression while HLA-A*24:02156Glnwas expressed at low levels in tapasin deficient cells. Peptides presented by these allelic variants showed distinct differences in features and repertoire. Immunoprecipitation experiments demonstrated all the HLA-A*24/156 variants to associate at similar levels with tapasin when present. Structurally, HLA-A*24:02 contains the residue triad Met97/His114/Gln156 and a Trp156 or Leu156 polymorphism provides tapasin independence by stabilizing these triad residues, thus generating an energetically stable and a more peptide receptive environment. Micropolymorphisms at position 156 can influence the generic peptide loading pathway for HLA-A*24 by altering their tapasin dependence for peptide selection. The trade-off for this tapasin independence could be the presentation of unusual ligands by these alleles, imposing significant risk following hematopoietic stem cell transplantation (HSCT).

scholarly journals Variations in HLA-B cell surface expression, half-life and extracellular antigen receptivity

eLife ◽  
2018 ◽  
Vol 7 ◽  
Author(s):  
Brogan Yarzabek ◽  
Anita J Zaitouna ◽  
Eli Olson ◽  
Gayathri N Silva ◽  
Jie Geng ◽  
...  
Keyword(s):  
Cell Surface ◽  
Half Life ◽  
Antigen Processing ◽  
Human Lymphocytes ◽  
Hla Class I ◽  
Surface Expression ◽  
Class I ◽  
Cell Surface Expression ◽  
Specific Expression ◽  
Hla Class I Molecules

The highly polymorphic human leukocyte antigen (HLA) class I molecules present peptide antigens to CD8+ T cells, inducing immunity against infections and cancers. Quality control mediated by peptide loading complex (PLC) components is expected to ensure the cell surface expression of stable peptide-HLA class I complexes. This is exemplified by HLA-B*08:01 in primary human lymphocytes, with both expression level and half-life at the high end of the measured HLA-B expression and stability hierarchies. Conversely, low expression on lymphocytes is measured for three HLA-B allotypes that bind peptides with proline at position 2, which are disfavored by the transporter associated with antigen processing. Surprisingly, these lymphocyte-specific expression and stability differences become reversed or altered in monocytes, which display larger intracellular pools of HLA class I than lymphocytes. Together, the findings indicate that allele and cell-dependent variations in antigen acquisition pathways influence HLA-B surface expression levels, half-lives and receptivity to exogenous antigens.

Sign in / Sign up

Export Citation Format

Share Document